一个新的治疗组合显示,高风险淋巴瘤病人的响应率为100%,结果良好,副作用可管理。 A new treatment combo showed 100% response in high-risk lymphoma patients, with strong results and manageable side effects.

在2025年ASH年度会议上提出的第3阶段试验发现,dronextamab与CHOP化疗相结合,在未处理扩散的、具有高风险特征的大B细胞淋巴瘤病人中,早期结果显著,在160毫克每周剂量下达到100%的回复率和完整回复率,结果可持久,安全情况可管理。 A phase 3 trial presented at the 2025 ASH Annual Meeting found that odronextamab combined with CHOP chemotherapy showed strong early results in untreated diffuse large B-cell lymphoma patients with high-risk features, achieving 100% response and complete response rates at the 160 mg weekly dose, with durable outcomes and a manageable safety profile. 选择了较高的剂量进行进一步研究。 The higher dose was selected for further study. 在另一个阶段的第二阶段试验中,Zanubrutinib在R-CHOP中增加的Zanubrutinib显示反应率高,存活率提高,特别是在有特定基因突变的病人中,这表明了进行个性化治疗的潜力。 In a separate phase 2 trial, zanubrutinib added to R-CHOP showed high response rates and improved survival, especially in patients with specific genetic mutations, suggesting potential for personalized treatment. 虽然对一些病人产生了严重的副作用,但这两种治疗方法一般都是良好的。 Both regimens were generally well-tolerated, though serious side effects occurred in some patients.